ReportGem ReportGem EN

普通外文研报

Strategic leap toward multi-modality CDMO

发布日期: 2026-07-21研究机构: Macquarie Research公司 / 股票: 207940.KS报告页数: 12原文语言: 英语证据页码: 8

研报英文原文证据摘录

Strategic leap toward multi-modality CDMO

Macquarie Equity Research Samsung Biologics

Alpha Model Decomposition Key Quant Findings

The quant model currently holds a reasonably positive The Macquarie Alpha is decomposed into its sector and

view on Samsung Biologics. The strongest style exposure is market relative factor & styles exposures (a higher/better

Quality, indicating this stock is likely to have a superior and percentile is coded in green, whilst lower in red).

more stable underlying earnings stream. The weakest style

exposure is Earnings Momentum, indicating this stock has relativePercentileto

received earnings downgrades and is not well liked by sell

sectors market

side analysts. Factors / Styles (/1205) (/782) Core factors in definition

ALPHA 92% 75% Built from the styles below

Macquarie Alpha Model: Key rankings VALUE 60% 18% Book, CF, Yield, Earnings Multiples

ANALYST 32% 49% Revisions (Earnings, Recommendations)

The Macquarie Quant’s flagship Alpha model is a dynamic MOMENTUM 49% 85% Price Momentum

multi-factor model based on a staple of quant factors such

as value, momentum, revisions, quality, and risk. GROWTH 17% 48% EPS, Sales (Forecast, Historic)

PROFITABILITY 73% 85% ROE, Margin, Asset Turnover

Global Market (Country) Sector

Pharma, Biotech QUALITY 96% 95% Accruals, Earn Stability, Cash Conversion Whole Universe Korea & Life Sciences

CAPITAL 86% 87% Investment/Capex, Net share issuance

Macquarie Alpha

4011/17997 193/782 94/1205 LIQUIDITY 18% 44% Size, Turnover, Analyst Coverage Model

Fundamental LOW RISK 98% 90% Beta, Volatility, Earn.Cert, Leverage 2448/17997 174/782 272/1205 (Consensus) *

TECHNICAL 12% 40% MACD, RSI, Bollinger, Williams R, etc

* based on Total Shareholder Return = Consensus Price target / Current Price

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器